Belgium· BE-AMP-SAM407601-00

Yervoy 5 mg/ml

A ipilimumab product containing ipilimumab, registered in Belgium by Bristol-Myers Squibb Pharma. The same ATC class is registered in 13 of our 19 countries.

ATC L01FX04

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedYervoy 5 mg/mlATCL01FX04REGISTER NO.BE-AMP-SAM407601-00PACKS LISTED3CHECKEDSeptember 26, 2026

Where it is registered

Ipilimumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L01FX04 (ipilimumab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose

Ipilimumab · ATC L01FX04

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ipilimumab costs, country by country.

Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Ipilimumab · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$884.82
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Ipilimumab
Manufacturer
Bristol-Myers Squibb Pharma
Country
Belgium (BE)
ATC code
L01FX04
ATC class
Ipilimumab
Defined daily dose
10 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 3

  • be_apb
    0751081
  • be_apb
    3666294
  • be_apb
    2932036

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

157 interactions on record for ipilimumab.

Graded by severity as the source publishes them — 25 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ipilimumab · interactions on record

157 records

  • 25 severe
  • 132 moderate

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • DalteparinB01AB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ipilimumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ipilimumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Yervoy
  • Liechtenstein · Yervoy
  • Norway · Yervoy

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f7673eac-1e02-4bed-8dd5-4dc1ff06cc2d
GET /v1/drugs/f7673eac-1e02-4bed-8dd5-4dc1ff06cc2d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentrate for solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Yervoy 5 mg/ml",
  "name_fr": "Yervoy 5 mg/ml",
  "name_nl": "Yervoy 5 mg/ml",
  "amp_code": "SAM407601-00",
  "strengths": [
    "5.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Ipilimumab",
    "Mannitol",
    "Sodium Chloride",
    "Sodium Hydroxide",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Ipilimumab",
  "authorisation_numbers": [
    "EU/1/11/698/001"
  ]
}

See everything about ipilimumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.